When science and passion connect, innovation happens. The oncology community shares a common mission: to transform the way patients live with cancer and related diseases. At Taj Oncology, we are passionate about the discovery and development of innovative medicines. We seek to provide a broad range of new therapies as well as practical solutions to advance the care of patients.
With nearly 7,000 employees operating in 55 countries, Taj Oncology has a truly global reach. We have the advantage of extraordinarily talented and globally diverse employees who, through shared goals and different perspectives, are dedicated to transforming the lives of patients living with cancer around the world. We have developed five new practice-changing medicines in the past decade, addressing unmet medical needs in patients worldwide. Our broad pipeline includes 27 new molecular entities in development, targeting key molecular pathways in cancer biology.
Connecting within the oncology community
Making connections in science and building relationships with people in the oncology community fuels our ability to deliver innovative medicines for patients. More than a decade ago, Taj AG was the first company to form a dedicated global business unit for developing and launching innovative oncology medicines that address the unmet medical needs of patients. This early vision has led to one of the most dynamic portfolios of new products in the marketplace.
Turning scientific possibility into clinical reality
A decade of success in oncology drug development has taught us the value of our connections within the oncology community and their importance to innovation. Together, we explore novel compounds in clinical development, many with potential best-in-class status, aiming to advance or create new standards of care. Our strategy is composed of three elements:
- Targeted research accelerates development and improves results.
- Collaboration leads to breakthroughs.
- Patient-inspired solutions provide more than medicine.
Unique, dedicated global capabilities support our strategy.
Taj Pharma Group
A dream for new world Anchored in India and committed to its traditional values of leadership with trust, the Taj Pharma Group is spreading its footprint globally through excellence and innovation.
Each operating company in the group develops its international business as an integral element in an overall strategy, depending on the competitive dynamics of the industry in which it operates. For some businesses a focus on the export market remains the priority. For others it is developing a robust presence in domestic markets given growing population of India. And then there are Group companies, a small but growing number, that have global ambitions; additionally, synchronizing these ventures to cater Indian market remains a priority for growth.
Exports from India remain the cornerstone of the Taj Pharma Group’s international business, but different Taj companies are increasingly investing in assets overseas through Greenfield projects (such as in Spain, Germany, Middle East, Africa, Russia, and CIS Countries), joint ventures (in Sri Lanka, UK) and acquisitions.
While individual Taj companies have differing geographical imperatives, the Taj group is focusing on a clutch of priority countries, which are expected to be of strategic importance in the years ahead. The regions are UK, Sri Lanka, the Netherlands, Germany, South Africa, members of the Gulf Cooperation Council, Brazil, Vietnam, Thailand and Taiwan.
Dr. R.K.Singh, Chairman, Taj Pharmaceuticals Limited., sums up the Taj group’s efforts to internationalize its operations thus: “We hope that a several years from now we will spread our wings far beyond India, that we become a global group, operating in many countries, an Indian business conglomerate that is at home in the world, carrying the same sense of trust that we do today." We have already progressed on such efforts by our current presence in more than 40 countries.